Published by Coherent Market Insights
Posted on September 21, 2021
4 min readLast updated: February 4, 2026
The Plasma Fractionation Market is projected to grow significantly by 2027, driven by an aging population and technological advancements.
Coherent Market Insights report on the Plasma Fractionation Market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators for the said market during the forecast period from 2021 to 2027. The report provides the overall market value of the Plasma Fractionation Market for the period of 2021 to 2027, with 2020 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the Plasma Fractionation Market for the forecast period.
The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/529
Plasma fractionation refers to the medical practices of separating the antigens from the plasma of red blood cells, which in turn results in the formation of plasma. This separation results in higher concentrations of antigens than those found in whole blood. Plasma fractionation also leads to more efficient processing of drugs. Over the years, immunoglobulin has been used in the treatment of various diseases including lupus, myositis, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, and neurological diseases such as multiple sclerosis. As a matter of fact, regulatory agencies are granting approval immunoglobulin for some other diseases as well. Recently, in November 2020, Eli Lily and Company received the U.S. Food and Drug Administration (FDA) emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Hence, such factors can stimulate growth of the plasma fractionation market.
Another factor that could aid growth of the market in discussion is the rapidly increasing geriatric population. Compared to other demographics, elderly people are more susceptible to different types of diseases due to the weakened immune systems. As per the World Health Organization (WHO), by 2050, the global population aged 65 years and above is expected to reach around 2 billion increasing from 900 million in 2015. Thus, these factors can augment growth of the plasma fractionation market. Recently, in July 2020, Grifols S.A., a Spanish plasma-derived medicines company, acquired GC Pharma’s plasma fractionation facility in Montreal, Canada for US$ 460 million.
Plasma fractionated antibodies are also giving new hope to medical healthcare all over a wide spectrum of autoimmune, heredity-related diseases. Recent clinical trials have proved that plasma-derived antibodies can efficiently fight against diseases such as Parkinson’s disease and rheumatoid arthritis. When it comes to regional impact, North America seems to be gaining significant traction in the plasma fractionation market. This is due to the early adoption of advanced technologies and growing healthcare expenditure across the region. On the contrary, Asia Pacific is exhibiting a positive outlook due to improve healthcare infrastructure across emerging economies such as India and China.
Several diseases that plasma protein therapeutics can treat include cardiovascular and endocrine disorders, autoimmune diseases, cancers, HIV/AIDS, inflammatory diseases, neurological disorders, and infections. There are several experimental treatments using antigens derived from plasma fractionated antibodies in clinical trials for several diseases. That being said, there are certain factors that can pose major challenges to the potential development of the market. For instance, plasma fractionation is expensive and has limited reimbursement options. Besides, the emergence of recombinant alternatives and stringent government regulations can impede growth of the plasma fractionation market in the near future.
Top Key Players Include In Plasma Fractionation Market: CSL Ltd., Octapharma AG, Grifols S.A, Baxalta Incorporated, Octapharma AG, and Kedrion S.p.A, Bio Products Laboratory, Sanquin, China Biologic Products, Inc., Biotest AG, and Laboratoire Français du Fractionnement et des Biotechnologies.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/529
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Plasma Fractionation Market will generate massive revenue by 2027 according to forecasts by CMI appeared first on Gatorledger.
The article discusses the growth and trends in the Plasma Fractionation Market projected to 2027.
An increasing geriatric population and advancements in healthcare technology are key drivers.
High costs, limited reimbursement options, and regulatory issues pose challenges.
Explore more articles in the Research Reports category
